A Phase II Trial to Assess the Efficacy and Safety of Pembrolizumab for Ovarian Squamous Cell Carcinoma
Status:
Not yet recruiting
Trial end date:
2027-04-30
Target enrollment:
Participant gender:
Summary
This is a phase II, non-randomized, open-label, single-arm, multicenter study to evaluate the
efficacy and safety of MK-3475 in patients with ovarian squamous cell carcinoma.